Molecular and clinical aspects of targeting the VEGF pathway in tumors

Grzegorz Korpanty, Laura A. Sullivan, Elizabeth Smyth, Desmond N. Carney, Rolf A. Brekken

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Tumor angiogenesis is a complex process resulting from many signals from the tumor microenvironment. From preclinical animal models to clinical trials and practice, targeting tumors with antiangiogenic therapy remains an exciting area of study. Although many scientific advances have been achieved, leading to the development and clinical use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib, these therapies fall short of their anticipated benefits and leave many questions unanswered. Continued research into the complex signaling cascades that promote tumor angiogenesis may yield new targets or improve upon current therapies. In addition, the development of reliable tools to track tumor responses to antiangiogenic therapy will enable a better understanding of current therapeutic efficacy and may elucidate mechanisms to predict patient response to therapy.

Original languageEnglish (US)
Article number652320
JournalJournal of Oncology
DOIs
StatePublished - 2010

Fingerprint

Vascular Endothelial Growth Factor A
Neoplasms
Therapeutics
Tumor Microenvironment
Animal Models
Clinical Trials
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Molecular and clinical aspects of targeting the VEGF pathway in tumors. / Korpanty, Grzegorz; Sullivan, Laura A.; Smyth, Elizabeth; Carney, Desmond N.; Brekken, Rolf A.

In: Journal of Oncology, 2010.

Research output: Contribution to journalArticle

Korpanty, Grzegorz ; Sullivan, Laura A. ; Smyth, Elizabeth ; Carney, Desmond N. ; Brekken, Rolf A. / Molecular and clinical aspects of targeting the VEGF pathway in tumors. In: Journal of Oncology. 2010.
@article{dc7516a946e74d9cb3cf968f997b1c22,
title = "Molecular and clinical aspects of targeting the VEGF pathway in tumors",
abstract = "Tumor angiogenesis is a complex process resulting from many signals from the tumor microenvironment. From preclinical animal models to clinical trials and practice, targeting tumors with antiangiogenic therapy remains an exciting area of study. Although many scientific advances have been achieved, leading to the development and clinical use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib, these therapies fall short of their anticipated benefits and leave many questions unanswered. Continued research into the complex signaling cascades that promote tumor angiogenesis may yield new targets or improve upon current therapies. In addition, the development of reliable tools to track tumor responses to antiangiogenic therapy will enable a better understanding of current therapeutic efficacy and may elucidate mechanisms to predict patient response to therapy.",
author = "Grzegorz Korpanty and Sullivan, {Laura A.} and Elizabeth Smyth and Carney, {Desmond N.} and Brekken, {Rolf A.}",
year = "2010",
doi = "10.1155/2010/652320",
language = "English (US)",
journal = "Journal of Oncology",
issn = "1687-8450",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Molecular and clinical aspects of targeting the VEGF pathway in tumors

AU - Korpanty, Grzegorz

AU - Sullivan, Laura A.

AU - Smyth, Elizabeth

AU - Carney, Desmond N.

AU - Brekken, Rolf A.

PY - 2010

Y1 - 2010

N2 - Tumor angiogenesis is a complex process resulting from many signals from the tumor microenvironment. From preclinical animal models to clinical trials and practice, targeting tumors with antiangiogenic therapy remains an exciting area of study. Although many scientific advances have been achieved, leading to the development and clinical use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib, these therapies fall short of their anticipated benefits and leave many questions unanswered. Continued research into the complex signaling cascades that promote tumor angiogenesis may yield new targets or improve upon current therapies. In addition, the development of reliable tools to track tumor responses to antiangiogenic therapy will enable a better understanding of current therapeutic efficacy and may elucidate mechanisms to predict patient response to therapy.

AB - Tumor angiogenesis is a complex process resulting from many signals from the tumor microenvironment. From preclinical animal models to clinical trials and practice, targeting tumors with antiangiogenic therapy remains an exciting area of study. Although many scientific advances have been achieved, leading to the development and clinical use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib, these therapies fall short of their anticipated benefits and leave many questions unanswered. Continued research into the complex signaling cascades that promote tumor angiogenesis may yield new targets or improve upon current therapies. In addition, the development of reliable tools to track tumor responses to antiangiogenic therapy will enable a better understanding of current therapeutic efficacy and may elucidate mechanisms to predict patient response to therapy.

UR - http://www.scopus.com/inward/record.url?scp=77954619947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954619947&partnerID=8YFLogxK

U2 - 10.1155/2010/652320

DO - 10.1155/2010/652320

M3 - Article

C2 - 20628530

AN - SCOPUS:77954619947

JO - Journal of Oncology

JF - Journal of Oncology

SN - 1687-8450

M1 - 652320

ER -